When was Pharnext founded?

Pharnext was founded in 2007 and raised its 1st funding round within a year of its incorporation.

Where is Pharnext located?

Pharnext is headquartered in Issy les Moulineaux, France.

How many employees does Pharnext have?

As of May 31, 2026, the latest employee count at Pharnext is 19.

Is Pharnext a funded company?

Pharnext is a funded company, having raised a total of $23.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2007.

When was the latest funding round of Pharnext?

Pharnext's latest funding was a $***** Post IPO round on Mar 2020, with participation from 0 investor. Its primary sector is Neurology. In France, the Neurology sector has seen $56M in funding in 2026 to date.

Where does Pharnext rank among its competitors?

Pharnext ranks 98th amongst 457 active competitors, of which 161 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Pharnext?

Pharnext's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Pharnext - 2026 Company Profile, Team, Funding & Competitors

Pharnext is a public company based in Issy les Moulineaux (France), founded in 2007 by Daniel Cohen. It operates as a Developer of therapeutics for the treatment of neurological diseases. Pharnext has raised $23.4M in funding. The company has 457 active competitors, including 161 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Developer of therapeutics for the treatment of neurological diseases. The company's product line include PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for neurodegenerative diseases.

Website: pharnext.com
Social

Key Metrics

Founded Year

2007

Location

Issy les Moulineaux, France

Stage

Public

Total Funding

$23.4M in 6 rounds

Latest Funding Round

Post IPO, Mar 2020, $*****

Investors

IPF Partners & 5 more

Ranked

98^th among 457 active competitors

Employee Count

19 as on May 31, 2026

Similar Companies

Denali Therapeutics & 567 more

Exit Details

Public

View Pharnext's full profile

Pharnext got listed on Jul 18, 2016.

Click here to take a look at Pharnext's IPO in detail

Pharnext has raised a total funding of $23.4M over 6 rounds. Its first funding round was on Dec 2007. Pharnext has 6 institutional investors.

Here is the list of recent funding rounds of Pharnext:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 2020	9889938	Post IPO	9221158	2596198	7028184	6468342
Apr 11, 2018	8330205	Post IPO	8784294	7714071	1766324	7216191
Dec 2011	9268997	Series B	8546420	3981261	2593896	Parinvest Asset Management & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Pharnext's funding rounds and investors

The founders of Pharnext is Daniel Cohen.

Here are the details of Pharnext's key team members:

Daniel Cohen: Founder of Pharnext. They serve on the boards of 2 companies.

View details of Pharnext's Founder profiles and Board Members

Pharnext's employee count trend

Pharnext has 19 employees as of May 26. Here is Pharnext's employee count trend over the years:

Uncover Pharnext's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pharnext include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Pharnext, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
98th	Pharnext 2007, Issy les Moulineaux (France), Public	Developer of therapeutics for the treatment of neurological diseases	$23.4M	IPF Partners, Kreos Capital & 4 others	46/100